Diamyd Medical AB
Company Profile
Business description
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company’s activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
Contact
Kungsgatan 29
StockholmSE-111 56
SWET: +46 86610026
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 August 2026
Employees
45
Stocks News & Analysis
stocks
Australia’s oldest REIT undervalued
stocks
Stop asking if there’s a stock market bubble. Ask this instead.
stocks
Are negative AI narratives holding this ASX share back?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,931.40 | 71.60 | -0.80% |
| CAC 40 | 8,378.49 | 25.50 | -0.30% |
| DAX 40 | 25,008.34 | 12.53 | 0.05% |
| Dow JONES (US) | 52,319.20 | 136.46 | 0.26% |
| FTSE 100 | 10,455.39 | 41.73 | -0.40% |
| HKSE | 22,881.02 | 145.66 | -0.63% |
| NASDAQ | 26,213.72 | 393.58 | 1.52% |
| Nikkei 225 | 70,474.96 | 412.64 | 0.59% |
| NZX 50 Index | 13,610.50 | 11.16 | -0.08% |
| S&P 500 | 7,499.36 | 58.93 | 0.79% |
| S&P/ASX 200 | 8,722.90 | 71.70 | -0.82% |
| SSE Composite Index | 4,094.40 | 20.50 | 0.50% |